Elvina Almuradova, Associate Professor at Medicana Health Group, shared a post on LinkedIn:
“ESPAC4 Long-Term Results in Journal of Clinical Oncology.
Overall Survival (OS):
– GemCap: 31.6 months vs Gemcitabine: 28.4 months (HR = 0.83; P = .031)
– R0 patients: GemCap: 49.9 months vs Gemcitabine: 32.2 months (HR = 0.63; P = .002)
– Lymph Node-Negative Patients: 5-Year OS: 59% (GemCap) vs 53% (Gemcitabine) (HR = 0.63; P = .04)
– No difference in lymph node-positive patients (P = .225).
– PRODIGE24 Ineligible Subgroup (193 Patients):Median OS: 25.9 months (GemCap) vs 20.7 months (Gemcitabine) (HR = 0.71; P = .038)
GemCap is a standard option for patients not eligible for mFOLFIRINOX and is particularly effective in R0 resection and lymph node-negative cases.”
